Tarlatamab
- Generic Name
- Tarlatamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2307488-83-9
- Unique Ingredient Identifier
- 74X82ST8Q1
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 240
- Registration Number
- NCT06745323
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 100
- Registration Number
- NCT06598306
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Belgium
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdansk, Poland
🇨ðŸ‡Kantonsspital Graubuenden, Chur, Switzerland
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 30
- Registration Number
- NCT06502977
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of Army Medical University, PLA, Chongqing, Chongqing, China
🇨🇳Harbin Meidical University Cancer Hospital, Harbin, Heilongjiang, China
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 550
- Registration Number
- NCT06211036
- Locations
- 🇺🇸
Franciscan Health Indianapolis, Indianapolis, Indiana, United States
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Jiamusi Cancer Hospital, Jiamusi, Heilongjiang, China
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT06117774
- Locations
- 🇨🇳
Northern Jiangsu Peoples hospital, Yangzhou, Jiangsu, China
🇨🇳Jiangxi Cancer hospital, Nanchang, Jiangxi, China
🇨🇳The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Amgen
- Registration Number
- NCT06064500
- Locations
- 🇮🇱
Hadassah University Hospital-Ein Kerem, Jerusalem, Israel
🇺🇸Yale School of Medicine, New Haven, Connecticut, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 509
- Registration Number
- NCT05740566
- Locations
- 🇧🇪
Vitaz campus Sint-Niklaas Moerland, Sint-Niklaas, Belgium
🇧🇷Beneficencia Portuguesa de Sao Paulo - Bp, Sao Paulo, São Paulo, Brazil
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
- Conditions
- Interventions
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 340
- Registration Number
- NCT05361395
- Locations
- 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Christiana Care Health Services, Newark, Delaware, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 222
- Registration Number
- NCT05060016
- Locations
- 🇺🇸
University of Pittsburgh Medical Center Cancer Pavillion, Pittsburgh, Pennsylvania, United States
🇬🇷Metropolitan Hospital, Athens, Greece
🇬🇷Agios Loukas Clinic, Thessaloniki, Greece
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 23
- Registration Number
- NCT04885998
- Locations
- 🇧🇪
Universitair Ziekenhuis Leuven - Campus Gasthuisberg, Leuven, Belgium
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇦🇹Universitaetsklinikum Allgemeines Krankenhaus Wien, Wien, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.